# NTX-301 in MDS/AML

> **NCT04167917** · PHASE1 · COMPLETED · sponsor: **University of Alabama at Birmingham** · enrollment: 22 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- Chronic Myelomonocytic Leukemia

## Interventions

- **DRUG:** NTX-301

## Key facts

- **NCT ID:** NCT04167917
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-06
- **Primary completion:** 2025-04-24
- **Final completion:** 2025-04-24
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04167917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04167917, "NTX-301 in MDS/AML". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04167917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*